American Express Introduces Maison Amex: An Exclusive Venue during Canadian Grand Prix Weekend in Montreal
TORONTO, June 4, 2025 /CNW/ - American Express Canada, the Official Payments Partner of Formula 1 is launching Maison Amex, a bespoke pit stop for select Cardmembers during the FORMULA 1 PIRELLI GRAND PRIX DU CANADA 2025 race weekend. Located in the heart of Montréal, Maison Amex is an exclusive lounge to relax and refuel with complimentary snacks by Chef Danny Smiles of Le Violon, which was recently ranked #1 Best New Restaurant by Canada's 100 Best in 2025.
"We want our Cardmembers to walk away from our experiences feeling inspired, valued and certain that only Amex could have delivered on something so memorable," said Kim Kuzmak, Vice President of Lifestyle Benefits, Partnerships and Brand at American Express Canada. "Whether it's access to Maison Amex or the many on-site benefits we offer at the track, Cardmembers visiting Montreal for F1 will encounter meaningful experiences that reflect their passions and bring the value of Amex Membership to life."
Access to Maison Amex will be available on a first-come, first-served basis. Details include:
When: Thursday, June 12– Sunday, June 15, 2025
Open 11:00 a.m. – 11:00 p.m. ET daily
Where: 1405 Stanley St, Montreal, Quebec H3B 1H8
Eligible Cardmembers: Cardmembers with one of the following cards are eligible to attend Maison Amex: The Platinum Card®, American Express® Aeroplan®* Reserve Card, Business Platinum Card® from American Express, American Express® Aeroplan®* Business Reserve Card, American Express® Air Canada®* Card, The Centurion Card®, Corporate Platinum Card® from American Express, American Express® Aeroplan®* Corporate Reserve Card.
Access to Maison Amex includes:
Access for one (1) Eligible Cardmember and one (1) guest to Maison Amex
Beverages available for purchase. Cardmember and Guest must be of legal drinking age to enter the venue
Complimentary snacks by Chef Danny Smiles of Le Violon
As an Official Partner of Formula 1, Amex brings incredible access and experiences to Cardmembers and F1 fans around the world. American Express Cardmembers attending the FORMULA 1 PIRELLI GRAND PRIX DU CANADA 2025 will have access to on-site benefits including:
Amex Trackside Lounge: Eligible Cardmembers * can visit the Amex Trackside Lounge on race weekend to reserve their spot for an exclusive trackside viewing experience. Capacity is limited. Terms Apply.
Amex Fan Experience: Available to all Amex Cardmembers and race attendees, fans can visit the Parc Zone to put their F1® skills to the test with trivia, film their driver intro, and design a custom livery. Capacity is limited.
Amex Race Radios: Amex Cardmembers get access to complimentary Race Radios, so you never have to miss a moment of the F1® action. Pick up a radio at Amex Race Radio kiosks around the track and listen to live F1® and F1 Academy commentary throughout race weekend. Limit one Race Radio per Cardmember, per day. While supplies last.
Amex Pit Stop: Amex Cardmembers can pick up a seat cushion and water bottle carrier by the hairpin turn to stay comfortable at the track. Limit one per Cardmember, per day. While supplies last.
For additional information on FORMULA 1 PIRELLI GRAND PRIX DU CANADA benefits for American Express Cardmembers visit: go.amex/canadiangp
The F1 logo, FORMULA 1, F1, GRAND PRIX and related marks are trademarks of Formula One Licensing BV, a Formula 1 company. All rights reserved.
TM, ®: Used by Amex Bank of Canada under license from American Express.
* Cardmembers with one of the following cards are eligible to visit the Trackside Lounge: The Platinum Card®, American Express® Aeroplan®* Reserve Card, Business Platinum Card® from American Express, American Express® Aeroplan®* Business Reserve Card, American Express® Air Canada®* Card, The Centurion Card®, Corporate Platinum Card® from American Express, American Express® Aeroplan®* Corporate Reserve Card.
About American Express
Amex (NYSE: AXP) is a global, premium payments and lifestyle brand powered by technology. Our colleagues around the world back our customers with differentiated products, services and experiences that enrich lives and build business success.
Founded in 1850 and headquartered in New York, Amex' brand is built on trust, security, and service, and a rich history of delivering innovation and Membership value for our customers. With a hundred million merchant locations on our global network in over 200 countries and territories, we seek to provide the world's best customer experience every day to a broad range of consumers, small and medium-sized businesses, and large corporations.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
7 minutes ago
- Cision Canada
Charlotte's Web Reports Year-Over-Year Growth For Q2 2025
Second Consecutive Quarter of Year-over-Year Revenue Growth Supported by New Product Innovations and Omnichannel Expansion LOUISVILLE, Colo., Aug. 13, 2025 /CNW/ - (TSX: CWEB) (OTC: CWBHF), Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), a botanical wellness innovation company and the market leader in cannabidiol (CBD) hemp extract wellness products, today announced results for the quarter ended June 30, 2025, reporting its second consecutive year-over-year revenue increase since 2021, building on the sequential quarterly growth trend achieved in 2024. All amounts are expressed in U.S. dollars. "Q2 marked another step forward in our turnaround as Charlotte's Web again delivered both sequential and year-over-year growth, demonstrating continued progress in revenue and strategic execution across omnichannel, innovation, and cost structure," said Bill Morachnick, Chief Executive Officer. "We successfully commenced in-house production of our new Brightside™ gummies and extended our omnichannel reach while achieving early success with our new product categories. With operational momentum building and strong early traction across new product categories, we remain confident in our ability to execute and deliver on our 2025 outlook." Operational improvements initiated in 2024 have continued to reduce costs year-over-year. In-house gummy production expanded in Q2, with Brightside™ fully internalized and additional gummy SKUs transitioning in the second half. The Company anticipates approximately $3 million in annualized cost savings from these internalization efforts and is evaluating further transitions in topical production for 2026. Erika Lind, Chief Financial Officer, added, "Our revenue growth was accompanied by rigorous SG&A discipline that reduced second quarter expenses 31.7% year-over-year. Post-quarter, we've implemented additional measures to reduce our annualized run rate by more than $6 million in 2026. Combined with our transition to in-house manufacturing, which will benefit profit margins over time, this disciplined cost management and modest revenue growth positions us to approach positive cash flow." Second Quarter Business Review Omnichannel Growth and Digital Activation Charlotte's Web's upgraded digital platform and expanded marketplace footprint – including TikTok Shop, Amazon, and Faire – continue to contribute incremental sales and brand exposure. With mushroom wellness gummies now available across all major platforms, digital revenue contribution has diversified further, balancing direct-to-consumer and omnichannel exposure. Brightside™ THC Gummies and Innovation Demand Launched during the second quarter, Brightside™, the Company's hemp-derived THC gummy line using patented TiME INFUSION ® technology, demonstrated rapid uptake and product velocity. Multiple SKUs sold out over the Memorial Day weekend, exceeding internal forecasts and requiring expedited restocking. The Company now produces Brightside gummies entirely in-house, providing improved margins, accelerated new product timelines, and enhanced quality control. Botanical Product Diversification Charlotte's Web continued to expand its botanical wellness portfolio beyond traditional CBD offerings in the second quarter, advancing into adjacent high-growth categories. Building on the success of the Company's CBN Stay Sleep Gummies—now its second-best-selling gummy product—Charlotte's Web introduced CBG Focus & Attention Gummies, addressing the growing U.S. nootropics market with a plant-based alternative to synthetic nootropics. The U.S. CBG category has posted significant year-over-year growth, reflecting rising consumer demand for natural cognitive enhancement. The Company's CBG launch demonstrates the Company's ability to leverage its botanical expertise to capture share in high-growth cannabinoid wellness segments and extend its leadership beyond traditional CBD. Extending this innovation momentum beyond cannabinoids, the Company's functional mushroom gummies portfolio—introduced in Q4 2024—features formulations for Focus, Stress Support, Energy, and Muscle Recovery. Crafted with premium botanical ingredients such as Lion's Mane, Reishi, Cordyceps, and Turkey Tail, these products are developed with the same commitment to quality and efficacy that defines Charlotte's Web's hemp portfolio. This expansion strengthens the Company's position in the high-growth functional mushroom category while further diversifying revenue streams beyond hemp wellness. Regulatory Progress Charlotte's Web continues to work closely with industry coalitions to advance comprehensive federal regulation of hemp-derived products. The Company believes the regulatory landscape is evolving more favorably with recent developments in Washington that signal renewed momentum for establishing clear regulatory pathways for CBD and other hemp extracts. With key Congressional hemp champions now in leadership positions, both House and Senate leaders have signaled their intention to introduce comprehensive legislation providing FDA authority to regulate CBD products as dietary supplements and food ingredients. The Company expects a regulated market will consolidate the industry in favor of established, quality-focused brands with proven track records. The U.S. CBD market has potential to accelerate under a clear federal framework. Charlotte's Web's history of compliance, quality standards, and brand trust positions the Company to capture disproportionate value as regulations emerge. DeFloria Clinical Progress DeFloria, Inc.—a collaboration between Charlotte's Web, Ajna BioSciences, and with initial funding from a division of British American Tobacco—has commenced FDA-cleared Phase 2 clinical trials for AJA001 Oral Solution to treat irritability associated with autism spectrum disorder ("ASD"). Charlotte's Web retains exclusive manufacturing rights for commercial supply of this botanical drug candidate, representing a potential long-term revenue opportunity in the multi-billion-dollar ASD treatment market. Second Quarter 2025 Financial Review The following table sets forth selected financial information for the periods indicated: Quarterly revenue trend: Consolidated net revenue for Q2 2025 was $12.8 million, a year-over-year increase of 4.2% from $12.3 million in Q2 2024. Growth was underpinned by consumer demand for Charlotte's Web's diversified botanical wellness innovations, including the Company's expanding functional mushroom gummies portfolio, newly launched CBG Focus & Attention Gummies targeting the growing minor cannabinoid segment, and the new Brightside™ precision low-dose hemp THC gummy collection. Gross profit was $6.0 million, or 46.8% of revenue in Q2 2025, compared to $2.6 million, or 21.0% of revenue in Q2 2024, which included a $3.8 million non-cash inventory provision related to a one-time wholesale hemp biomass transaction. Excluding inventory provisions, Q2 2024 Adjusted Gross Profit 1 was $6.4 million, or 52.2% of revenue. Current quarter margin performance reflected insourcing startup costs associated with gummy production, certain zero-margin DeFloria extract sales to support its Phase 2 clinical trials (reducing overall gross margin by approximately three percentage points) and promotional activities during the Memorial Day sales campaign. Total selling, general, and administrative ("SG&A") expenses were $10.1 million for the quarter, a 31.7% improvement from $14.7 million in Q2 2024. The 31.7% decrease was primarily attributable to a decrease in amortization expense of $1.9 million related to the termination of the MLB Promotional Rights Agreement and a decrease in personnel costs between the comparable periods. This performance demonstrates the effectiveness of the comprehensive cost optimization strategy initiated in 2024 to better align operating expenses with revenue. As part of the ongoing commitment to disciplined cost management and operational efficiency, subsequent to the close of the second quarter of 2025, the Company has implemented additional expense reduction measures. Including cost savings from in-house manufacturing, these initiatives are expected to reduce the Company's annualized costs by approximately $9 million in 2026, supporting Charlotte's Web's trajectory toward positive cash flow. Total net loss for Q2 2025 was $6.3 million, or $(0.04) per share, compared to a net loss of $11.1 million, or $(0.07) per share, in Q2 2024. Adjusted EBITDA 1 for the quarter was $(3.6) million, a 30.8% improvement versus $(5.2) million in Q2 2024, supporting continued progress toward profitability. Cash and working capital as of June 30, 2025, were $15.3 million and $29.4 million, respectively. "Q2 demonstrated continued year-over-year progress in our financial transformation," said Ms. Lind. "For the first half of 2025, we've reduced our cash burn by 52.0% year-over-year while returning to growth. Our cash and working capital has us well-positioned to complete our return to positive cash flow. The combination of our dramatically lower operating expense base, expanding gross margins as we scale in-house production, and modest revenue growth requirements creates multiple paths to positive cash flow." Consolidated Financial Statements and Management's Discussion and Analysis The Company's consolidated financial statements and accompanying s for the three and six months ended June 30, 2025, and 2024, and related management's discussion and analysis of financial condition and results of operations ("MD&A"), are reported in the Company's 10-Q filing on the Securities and Exchange Commission website at and on SEDAR+ at and will be available on the Investor Relations section of the Company's website at Analyst Conference Call Management will host a conference call to discuss the Company's 2025 second quarter results at 11:00 A.M. ET on August 13, 2025. There are three ways to join the call: Register and enter your phone number at to receive an instant automated call back, or Dial 1-646-357-8785 or 1-800-836-8184 approximately 10 minutes before the conference call, or Listen to the live webcast online. Earnings Call Replay A recording of the call will be available through August 20, 2025. To listen to a replay of the earnings call please dial 1- 646-517-4150 or 1-888-660-6345 and provide conference replay ID 22439#. A webcast of the call will also be accessible through the investor relations section of the Company's website for an extended period of time. Subscribe to Charlotte's Web investor news. About Charlotte's Web Holdings, Inc. Charlotte's Web Holdings, Inc., a Certified B Corporation headquartered in Louisville, Colorado, is a botanical wellness innovation company and a market leader in hemp extract wellness that includes Charlotte's Web whole-plant full-spectrum CBD extracts as well as broad-spectrum CBD and cannabinoid isolates. The Company's hemp extracts have naturally occurring botanical compounds including cannabidiol ("CBD"), CBN, CBC, CBG, THC, terpenes, flavonoids, and other beneficial compounds. Charlotte's Web product categories include CBD oil tinctures (liquid products), CBD gummies (sleep, calming, exercise recovery, immunity), CBN gummies, hemp-derived THC microdose gummies, functional mushroom gummies, CBD capsules, CBD topical creams, and lotions, as well as CBD pet products for dogs. Through its substantially vertically integrated business model, Charlotte's Web maintains stringent control over product quality and consistency with analytic testing from soil to shelf for quality assurance. Charlotte's Web products are distributed to retailers and healthcare practitioners throughout the U.S.A. and are available online through the Company's website at Shares of Charlotte's Web trade on the Toronto Stock Exchange (TSX) under the symbol "CWEB" and are quoted in U.S. Dollars in the United States on the OTC under the symbol "CWBHF". Forward-Looking Information Certain information provided herein constitutes forward-looking statements or information (collectively, "forward-looking statements") within the meaning of applicable securities laws. Forward-looking statements are typically identified by words such as "may", "will", "should", "could", "anticipate", "expect", "project", "estimate", "forecast", "plan", "intend", "target", "believe" and similar words suggesting future outcomes or statements regarding an outlook. Forward-looking statements are not guarantees of future performance, and readers are cautioned against placing undue reliance on forward-looking statements. By their nature, these statements involve a variety of assumptions, known and unknown risks and uncertainties, and other factors which may cause actual results, levels of activity, and achievements to differ materially from those expressed or implied by such statements. The forward-looking statements contained in this press release are based on certain assumptions and analysis by management of the Company in light of its experience and perception of historical trends, current conditions, expected future development, and other factors that it believes are appropriate and reasonable. Specifically, this press release contains forward-looking statements relating to, but not limited to: organizational changes, marketing plans and operational platform upgrades, and the impact of these initiatives on retail expansion, operational efficiencies, cash flow, revenue and e-commerce monetization; expectations relating to IT upgrades, marketing optimization and operational integrations; product expansion activities and the corresponding results thereof; sales volume and gross margin expectations; anticipated timing for, and business impact of, in-house manufacturing of topical and gummy products; the impact of the Company's product innovations on product development; regulatory developments and the impact of developments on both consumer action and the Company's opportunities and operations; activities relating to, and sponsorship of, legislation to advance regulatory framework; the impact of insourcing on operating margins, capital expenditures and R&D anticipated consumer trends and corresponding product innovation; anticipated future financial results; the Company's ability to increase online traffic and demographic exposure through new products and marketing and omni-channel expansion; the impact of certain activities on the Company's business and financial condition and anticipated trajectory; continued product placement on various product channels; anticipated development of new products; the outcomes from DeFloria's clinical trials, including commercial opportunities for Charlotte's Web. The material factors and assumptions used to develop the forward-looking statements herein include, but are not limited to: expectations around cost reduction, run rate, revenue growth and cash flow for 2025 and 2026; regulatory regime changes; anticipated product development and sales; the success of sales and marketing activities; product development and production expectations; outcomes from R&D activities; the Company's ability to deal with adverse growing conditions in a timely and cost-effective manner; the availability of qualified and cost-effective human resources; compliance with contractual and regulatory obligations and requirements; availability of adequate liquidity and capital to support operations and business plans; and expectations around consumer product demand. In addition, the forward-looking statements are subject to risks and uncertainties pertaining to, among other things: supply and distribution chains; the market for the Company's products; revenue fluctuations; regulatory changes; loss of customers and retail partners; retention and availability of talent; competing products; share price volatility; loss of proprietary information; product acceptance; internet and system infrastructure functionality; information technology security; available capital to fund operations and business plans; crop risk; economic and political considerations; and including but not limited to those risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ending December 31, 2024, and other risk factors contained in other filings with the Securities and Exchange Commission available on and filings with Canadian securities regulatory authorities available The impact of any one risk, uncertainty, or factor on a particular forward-looking statement is not determinable with certainty, as these are interdependent, and the Company's future course of action depends on management's assessment of all information available at the relevant time. Any forward-looking statement in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. Except as required by applicable law, the Company assumes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. All forward-looking statements, whether written or oral, attributable to the Company or persons acting on the Company's behalf, are expressly qualified in their entirety by these cautionary statements. CHARLOTTE'S WEB HOLDINGS, INC. CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (in thousands of U.S. dollars, except share amounts) Common Shares Additional Paid-in Capital Accumulated Deficit Total Shareholders' Equity Shares Amount Balance—December 31, 2024 158,009,541 $ 1 $ 328,655 $ (301,569) $ 27,087 Common shares issued upon vesting of restricted share units, net of withholding — — — — — Share-based compensation — — 187 — 187 Net loss — (6,212) (6,212) Balance— March 31, 2025 158,009,541 $ 1 $ 328,842 $ (307,781) $ 21,062 Common shares issued upon vesting of restricted share units, net of withholding 608,226 — (25) — (25) Share-based compensation — — 180 — 180 Net loss — — — (6,288) (6,288) Balance—June 30, 2025 158,617,767 $ 1 $ 328,997 $ (314,069) $ 14,929 Balance—December 31, 2023 154,332,366 $ 1 $ 327,280 $ (271,723) $ 55,558 Common shares issued upon vesting of restricted share units, net of withholding 2,895,489 — (98) — (98) Share-based compensation — 842 — 842 Net loss — (9,634) (9,634) Balance—March 31, 2024 157,227,855 $ 1 $ 328,024 $ (281,357) $ 46,668 Common shares issued upon vesting of restricted share units, net of withholding 267,187 — (20) — (20) Share-based compensation — — 237 — 237 Net loss — — — (11,057) (11,057) Balance—June 30, 2024 157,495,042 $ 1 $ 328,241 $ (292,414) $ 35,828 (1) Non-GAAP Measures – Adjusted Gross Profit, EBITDA and Adjusted EBITDA Earnings before interest, taxes, depreciation, and amortization ("EBITDA") is not a recognized performance measure under U.S. GAAP. The term EBITDA consists of net income (loss) and excludes interest, taxes, depreciation, and amortization. Adjusted EBITDA also excludes other non-cash items such as changes in fair value of financial instruments (Mark-to-Market), Share-based compensation, and impairment of assets. The term Adjusted Gross Profit consists of gross profit before inventory provision, adjusted for inventory provision, net. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with GAAP. The non-GAAP financial measures do not have a standardized meaning prescribed under U.S. GAAP and therefore may not be comparable to similar measures presented by other issuers. The primary purpose of using non-GAAP financial measures is to provide supplemental information that we believe may be useful to investors and to enable investors to evaluate our results in the same way we do. We also present the non-GAAP financial measures because we believe they assist investors in comparing our performance across reporting periods on a consistent basis, as well as comparing our results against the results of other companies, by excluding items that we do not believe are indicative of our core operating performance. Specifically, we use these non-GAAP measures as measures of operating performance; to prepare our annual operating budget; to allocate resources to enhance the financial performance of our business; to evaluate the effectiveness of our business strategies; to provide consistency and comparability with past financial performance; to facilitate a comparison of our results with those of other companies, many of which use similar non-GAAP financial measures to supplement their GAAP results; and in communications with our board of directors concerning our financial performance. Investors should be aware, however, that not all companies define these non-GAAP measures consistently. Adjusted Gross Profit for the three and six months ended June 30, 2025, and 2024 is as follows: Adjusted EBITDA for the three months ended June 30, 2025, and 2024 is as follows: Charlotte's Web Holdings, Inc. Statement of Adjusted EBITDA (In Thousands) Three Months Ended Six Months Ended June 30, June 30, (unaudited) (unaudited) U.S. $ Thousands 2025 2024 2025 2024 Net income (loss) $ (6,288) $ (11,057) $ (12,500) $ (20,691) Depreciation of property and equipment and amortization of intangibles 512 2,489 2,961 4,982 Interest expense 450 493 1,135 980 Income tax expense 2 (46) 2 (62) EBITDA (5,324) (8,121) (8,406) (14,791) Stock Comp 180 237 367 1,079 Mark-to-market financial instruments 1,543 (1,140) 1,669 720 Inventory Provision (17) 3,830 (4) 3,926 Adjusted EBITDA $ (3,618) $ (5,194) $ (6,374) $ (9,066) SOURCE Charlotte's Web Holdings, Inc.
Cision Canada
38 minutes ago
- Cision Canada
Health Canada Approves KEYTRUDA® for Patients with Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma Tumours that are PD-L1 (CPS) Positive as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as Monotherapy Français
Approval is based on KEYNOTE-689 Phase III Clinical Trial Results KIRKLAND, QC, Aug. 13, 2025 /CNW/ -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has granted approval for KEYTRUDA ® (pembrolizumab), Merck's anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumours express PD-L1 (Combined Positive Score [CPS] ≥ 1), as determined by a validated test, as neoadjuvant treatment as monotherapy, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as monotherapy. The approval is based on data from the Phase 3 KEYNOTE-689 trial, which demonstrated positive clinical outcomes in patients with resectable locally advanced HNSCC whose tumours expressed PD-L1 (CPS ≥ 1). Perioperative KEYTRUDA ® in combination with adjuvant radiotherapy with or without cisplatin reduced the risk of event free survival (EFS) by 30% (Hazard Ration [HR]=0.70 [95% Confidence Interval [CI]: 0.55–0.89; p=0.0014]) compared to adjuvant radiotherapy with or without cisplatin. "We know that head and neck squamous cell carcinomas present significant treatment challenges because of their complexity," said André Galarneau, PhD, Executive Director & Vice President, Oncology Business Unit at Merck Canada. "The introduction of a perioperative anti-PD-1 treatment option for eligible patients in Canada represents an important development with the potential to make a meaningful difference for patients and their families impacted by this disease." About KEYNOTE-689 KEYNOTE-689 is a randomized, multicenter, open label, active-controlled Phase III trial ( NCT03765918) evaluating pembrolizumab in patients with resectable locally advanced (Stage III-IVA) head and neck squamous cell carcinoma (HNSCC). Randomization was stratified by primary tumour site (oropharynx/oral cavity vs. larynx vs. hypopharynx), tumour stage (III vs. IVA) and PD-L1 status (Tumour Proportion Score [TPS] ≥ 50% vs TPS < 50%). The study enrolled 714 patients who were randomized (1:1) to receive one of two treatment arms: Neoadjuvant pembrolizumab 200 mg for 2 cycles every 3 weeks prior to surgical resection. Within 6 weeks following surgery, pembrolizumab 200 mg for 3 cycles in combination with either radiation + 3 cycles of cisplatin 100 mg/m 2 every 3 weeks for patients with high-risk pathological features after surgery or radiation alone for patients without high-risk pathological features after surgery. This was followed by pembrolizumab 200 mg every 3 weeks for up to 12 cycles. No neoadjuvant treatment prior to surgery. Within 6 weeks following surgery, either radiation + 3 cycles of cisplatin 100 mg/m 2 every 3 weeks for patients with high-risk pathological features after surgery or radiation alone for patients without high-risk pathological features after surgery. High-risk pathological features included the presence of positive margins or extranodal extension following surgical resection. Treatment with pembrolizumab continued until completion of the treatment (17 cycles), disease progression that precluded definitive surgery, disease recurrence in the adjuvant phase, disease progression for those who did not undergo surgery or had incomplete resection and entered the adjuvant phase, or unacceptable toxicity. Assessment of tumour status was performed prior to surgery at Week 6 in the neoadjuvant phase. Following the start of the adjuvant phase, assessment of tumour status was performed 12 weeks after the end of RT ± cisplatin treatment and then every 3 months until the end of Year 3; then every 6 months thereafter up to the end of Year 5. The primary efficacy outcome measure was event-free survival (EFS) by Blinded Independent Central Review (BICR) defined as the time from randomization to the first occurrence of any of the following events: progression of disease that precludes definitive surgery, local or distant disease progression or recurrence, or death due to any cause. Secondary primary malignancy was not considered an event. An additional efficacy outcome measure was overall survival (OS). Among the CPS ≥1 population, at the time of the first pre-specified interim analysis, the EFS HR was 0.70 (95% CI, 0.55-0.89; p=0.00140) and the number of events was 128 (37%) in the pembrolizumab arm versus 156 (47%) in the RT +/- cisplatin arm. The median EFS was 59.7 months (95% CI, 37.9-not reached) versus 29.6 months (95% CI, 19.5-41.9), in the pembrolizumab and RT +/- cisplatin arms respectively. The most common treatment-related adverse events for patients treated with pembrolizumab in KEYNOTE-689 (reported in at least 20% of patients) were radiation skin injury and stomatitis. The most common Grade 3-5 treatment-related adverse events (reported in at least 5% of patients) were stomatitis (11.6%), lymphocyte count decreased (5.5%), and neutrophil count decreased (5.3%). For complete information, refer to the KEYTRUDA ® product monograph. About head and neck cancer Head and neck cancer are comprised of a group of cancers that develop in or around the mouth, nose, throat, sinuses, larynx or voice box and saliva glands. In Canada, it was estimated that there were approximately 8,100 new cases of head and neck cancer diagnosed and more than 2,100 deaths from the disease in 2024. Most head and neck cancers begin in the squamous cells that line the mucosal surfaces such as the mouth, throat and voice box. There are several factors that greatly increase the risk of developing head and neck cancer, including tobacco and alcohol use, human papillomavirus (HPV), occupation exposure to certain substances, genetic history and pool oral hygiene. About KEYTRUDA ® KEYTRUDA ® is an anti-programmed death receptor-1 (anti-PD-1) therapy that works by helping increase the ability of the body's immune system to help detect and fight tumour cells. KEYTRUDA ® is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumour cells and healthy cells. KEYTRUDA ® was first approved in Canada in 2015 and currently has indications in several disease areas, including advanced renal cell carcinoma, bladder cancer, non-small cell lung carcinoma, primary mediastinal B-cell lymphoma, classical Hodgkin lymphoma, colorectal cancer, endometrial carcinoma, cervical cancer, esophageal cancer, triple-negative breast cancer, melanoma, and head and neck squamous cell carcinoma. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable, and healthy future for all people and communities. For more information about our operations in Canada, visit and connect with us on LinkedIn @MerckCanada. Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2023 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site ( ® Merck Sharp & Dohme LLC. Used under license. © 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. CA-NON-04264 Media Contacts:
Toronto Star
12 hours ago
- Toronto Star
Acceleware Ltd. Announces Extension of Private Placement Financing
CALGARY, Alberta, Aug. 12, 2025 (GLOBE NEWSWIRE) — Acceleware® Ltd. ('Acceleware' or the 'Company') (TSX-V: AXE), a leading innovator of cutting-edge radio frequency ('RF') power-to-heat technologies targeting process heat for critical minerals, amine regeneration (for carbon capture and other applications), and enhanced oil production, is pleased to announce that the TSX Venture Exchange has agreed to extend the closing of additional tranches of its previously announced non-brokered private placement of units (the 'Units') that it previously announced on June 30, 2025 (the 'Private Placement'), to September 1, 2025. The first tranche of the Private Placement closed on July 31, 2025 for total gross proceeds of $791,334.20, as previously announced. Proceeds from the Private Placement will be used to fund a portion of the Company's RF XL 2.0 redeployment plan, to advance commercialization of new RF heating applications, including critical minerals applications and amine regeneration applications including carbon capture, and for general corporate purposes.
